DNA-topoisomerase I activity and content in epithelial ovarian cancer

Annals of Oncology

Volumn 9, Issue 3, 1998, Pages 313-319

  Codegoni, A M ^a   Castagna, S ^b   Mangioni, C ^b   Scovassi, A I ^c   Broggini, M ^a   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

Ovarian cancer; Topoisomerase I; Topoisomerase I inhibitors

Indexed keywords

DNA TOPOISOMERASE;

ARTICLE; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; METASTASIS POTENTIAL; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0031978169     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008207125986     Document Type: Article

References (21)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550-9 (published erratum appears in N Engl J Med 10 Feb 1994; 330 (6): 448, see comments).
2. Ozols RF. Treatment of ovarian cancer: Current status. Semin Oncol 1994; 21: 1-9.
3. McGuire WP, Hoskins WJ, Brady MF el al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6 (see comments).
4. Huinink WtB, Gore M, Carmichael J et al. Topotecan vs. paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-93.
5. Hsiang YH, Hertzberg R, Hecth S et al. Camtpthecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-8.
6. Ryan AJ, Squires S, Strutt HL et al. Camptothecin cytotoxicity in mammalian cells is associated ith the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 1991; 19: 3295-3300.
7. Nitiss JL, Wang JC. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 1996; 50: 1095-1102.
8. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995; 1262: 1-14.
9. van der Zee AG, Hollema H, de Jong S et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991; 51: 5915-20.
10. van der Zee AG, de Jong S, Keith WN et al. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 1994; 54: 749-55.
11. Cornarotti M, Capranico G, Bohm S et al. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer 1996; 67: 479-84.
12. Kotoh S, Naito S, Yokomizo A et al. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 1994; 54: 3248-52.
13. Madden KR, Champoux JJ. Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res 1992; 52: 525-32.
14. Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996; 74: 327-38 (Editorial).
15. D'Arpa P, Liu LF. Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. Exp Cell Res 1995; 217: 125-31.
16. Whitacre CM, Berger NA. Factors affecting topotecan-induced programmed cell death: Adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase. Cancer Res 1997; 57: 2157-63.
17. Beidler DR, Chang JY, Zhou BS et al. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 1996; 56: 345-53.
18. Wang L-F, Ting C-Y, Lo C-K et al. Identification of mutations at DNA topoisomerase Iresponsible for camptothecin resistance. Cancer Res 1997; 57: 1516-22.
19. Jansen WJM, Zwart B, Hulsker STM, et al. CPT-II in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants, Int J Cancer 1997; 70: 335-40.
20. Fujimori A, Harker WG, Kohlhagen G et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 1995; 55: 1339-46.
21. Fujimori A, Gupta M, Hoki Y et al. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol 1996; 50: 1472-8.